ECSP077372A - THROMBINE RECEIVER ANTAGONISTS - Google Patents

THROMBINE RECEIVER ANTAGONISTS

Info

Publication number
ECSP077372A
ECSP077372A EC2007007372A ECSP077372A ECSP077372A EC SP077372 A ECSP077372 A EC SP077372A EC 2007007372 A EC2007007372 A EC 2007007372A EC SP077372 A ECSP077372 A EC SP077372A EC SP077372 A ECSP077372 A EC SP077372A
Authority
EC
Ecuador
Prior art keywords
bond
thrombine
double bond
receiver antagonists
tricyclics
Prior art date
Application number
EC2007007372A
Other languages
Spanish (es)
Inventor
Mariappan V Chelliah
Yan Xia
Samuel Chackalamannil
Keith A Eagen
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP077372A publication Critical patent/ECSP077372A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)

Abstract

Se describen tricíclicos sustituidos con heterocíclicos de la fórmula o una sal o solvato de dicho compuesto, isómero o mezcla racémica donde representa un doble enlace optativo, la línea de puntos es optativamente un enlace o falta de enlace, para dar lugar a un doble enlace o un enlace simple, según lo permita el requerimiento de la valencia y donde A, B, G, M, X, J, n, Het, R3, R10, R11, R32 y R33 se definen en la presente y el resto de los sustituyentes son como se los definiera en la memoria descriptiva, así como composiciones farmacéuticas que los contienen y un método para el tratamiento de enfermedades asociadas con la trombosis, aterosclerosis, restenosis, hipertensión, angina de pecho, arritmia, insuficiencia cardiaca y cáncer mediante la administración de dichos compuestos. También se reivindica una terapia combinatoria con otros agentes cardiovasculares.Tricyclics substituted with heterocyclics of the formula or a salt or solvate of said compound, isomer or racemic mixture where it represents an optional double bond are described, the dotted line is optionally a bond or lack of bond, to give rise to a double bond or a simple link, as allowed by the valence requirement and where A, B, G, M, X, J, n, Het, R3, R10, R11, R32 and R33 are defined herein and the rest of the substituents they are as defined in the specification, as well as pharmaceutical compositions containing them and a method for the treatment of diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure and cancer by administering said compounds. Combinatorial therapy with other cardiovascular agents is also claimed.

EC2007007372A 2004-10-08 2007-04-04 THROMBINE RECEIVER ANTAGONISTS ECSP077372A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61751404P 2004-10-08 2004-10-08

Publications (1)

Publication Number Publication Date
ECSP077372A true ECSP077372A (en) 2007-05-30

Family

ID=36061549

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007372A ECSP077372A (en) 2004-10-08 2007-04-04 THROMBINE RECEIVER ANTAGONISTS

Country Status (17)

Country Link
US (1) US7488752B2 (en)
EP (2) EP1802609A2 (en)
JP (1) JP2008515899A (en)
KR (1) KR20070101216A (en)
CN (1) CN101072772A (en)
AR (1) AR054611A1 (en)
AU (1) AU2005294490A1 (en)
BR (1) BRPI0518159A (en)
CA (1) CA2582639A1 (en)
EC (1) ECSP077372A (en)
IL (1) IL182355A0 (en)
MX (1) MX2007004197A (en)
NO (1) NO20072344L (en)
RU (1) RU2408594C2 (en)
TW (1) TW200626584A (en)
WO (1) WO2006041872A2 (en)
ZA (1) ZA200702790B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
PE20080183A1 (en) * 2006-04-06 2008-03-10 Schering Corp TRA COMBINATION THERAPIES
US8828966B2 (en) * 2006-10-03 2014-09-09 Claire Mitchell Method for treatment of macular degeneration by modulating P2Y12 or P2X7 receptors
MX2009003761A (en) * 2006-10-04 2009-06-30 Schering Corp Bicyclic and tricyclic derivatives as thrombin receptor antagonists.
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
WO2008128038A2 (en) * 2007-04-13 2008-10-23 The Scripps Research Institute Methods and compositions for treating cardiac dysfunctions
PL2558462T3 (en) 2010-04-16 2015-03-31 Sanofi Sa Pyridyl-vinyl-pyrazolo-chinolines as PAR1 inhibitors
ES2532902T3 (en) 2010-04-16 2015-04-01 Sanofi Tricyclic pyridyl vinyl pyrroles as inhibitors of PAR1
WO2013134012A1 (en) 2012-03-06 2013-09-12 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
SG11201406973PA (en) * 2012-05-04 2014-12-30 Novartis Ag Complement pathway modulators and uses thereof
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
US9475806B2 (en) 2013-03-14 2016-10-25 Novartis Ag Complement factor B inhibitors and uses there of
US9808473B2 (en) 2013-08-22 2017-11-07 Merck Sharp & Dohme Corp. Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
WO2015026685A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
US9701669B2 (en) 2013-08-22 2017-07-11 Merck Sharp & Dohme Corp. Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists
CN104447927A (en) * 2013-09-13 2015-03-25 天津市汉康医药生物技术有限公司 Cangrelor monohydrate crystal and preparation method thereof
CN104447928A (en) * 2013-09-13 2015-03-25 天津市汉康医药生物技术有限公司 Cangrelor dihydrate
EP3089963A1 (en) 2013-10-30 2016-11-09 Novartis AG 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
WO2016058144A1 (en) * 2014-10-15 2016-04-21 Merck Sharp & Dohme Corp. Preparation and use of cyclic sulfonamide derivatives as par-1 receptor antagonists
CN105732595B (en) * 2015-12-22 2018-08-28 山东大学 PAR-1 inhibitor based on terpene derivant and preparation method thereof and the purposes in treating thrombotic diseases
TW201738237A (en) * 2016-04-22 2017-11-01 Jiangsu Tasly Diyi Pharmaceutical Co Ltd New himbacine analogue and uses thereof in medicines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Thrombin receptor antagonists and pharmaceutical compositions comprising them
SK285153B6 (en) * 1997-11-25 2006-07-07 Schering Corporation Heterocyclic-substituted tricyclic compound, pharmaceutical composition containing it and its use
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
KR100604742B1 (en) * 2000-06-15 2006-07-26 쉐링 코포레이션 Thrombin receptor antagonist
CA2463628A1 (en) * 2001-10-18 2003-04-24 Schering Corporation Himbacine analogues as thrombin receptor antagonists
US7086034B2 (en) * 2002-06-28 2006-08-01 Canon Kabushiki Kaisha Method, program, and storage medium for acquiring logs

Also Published As

Publication number Publication date
IL182355A0 (en) 2007-07-24
TW200626584A (en) 2006-08-01
AR054611A1 (en) 2007-07-04
EP2075250A2 (en) 2009-07-01
US7488752B2 (en) 2009-02-10
EP2075250B1 (en) 2015-03-04
RU2007116850A (en) 2008-11-20
AU2005294490A1 (en) 2006-04-20
CA2582639A1 (en) 2006-04-20
NO20072344L (en) 2007-07-04
US20060079684A1 (en) 2006-04-13
WO2006041872A2 (en) 2006-04-20
BRPI0518159A (en) 2008-11-04
JP2008515899A (en) 2008-05-15
KR20070101216A (en) 2007-10-16
CN101072772A (en) 2007-11-14
MX2007004197A (en) 2007-06-15
EP1802609A2 (en) 2007-07-04
EP2075250A3 (en) 2009-10-14
RU2408594C2 (en) 2011-01-10
WO2006041872A3 (en) 2007-01-04
ZA200702790B (en) 2008-09-25

Similar Documents

Publication Publication Date Title
CO6531452A2 (en) SUBSTITUTED PIPERIDINS THAT INCREASE THE ACTIVITY OF P53 AND ITS USES
MX2009003761A (en) Bicyclic and tricyclic derivatives as thrombin receptor antagonists.
MX2020008754A (en) Pharmaceutical compounds.
UY31050A1 (en) TRPV1 ANTAGONISTS AND USES OF THE SAME
CY1109369T1 (en) Substituted pyrrolopyridines, the compounds containing them, their manufacturing process and their use
PE20190811A1 (en) DERIVATIVES OF PYRAZOLOPYRIMIDINES AS A KINASE INHIBITOR
CR20110099A (en) PIRROLIDINA-2-SUBSTITUTED CARBOXAMIDS
CR11089A (en) IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULAR P2X7
PE20070018A1 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ASPARTILE PROTEASES
CR20120410A (en) PIRROLIDINA-2-SUBSTITUTED CARBOXAMIDS
UY30267A1 (en) NEW DERIVATIVES OF THIOXANTINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS
TW200626584A (en) Thrombin receptor antagonists
ECSP17007208A (en) DERIVATIVES OF INDANO AND INDOLINE AND THE USE OF THE SAME AS ACTIVATORS OF SOLUBLE GUANILATE CYCLASE
ECSP088484A (en) SPIROCYCLIC QUINAZOLINE DERIVATIVES AS PDE7 INHIBITORS
WO2006105217A3 (en) Spirocyclic thrombin receptor antagonists
CY1123880T1 (en) INNOVATIVE 5-HT2 COMPETITORS
MX376743B (en) SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS
PA8589601A1 (en) INDAZOL DERIVATIVES AS CRF ANTAGONISTS
UY28906A1 (en) PIRIMIDINE DERIVATIVES THAT ARE ANTAGONISTS OF THE VITRONECTINE RECEPTOR
CO6341557A2 (en) NITROGEN DERIVATIVES OF PANCRATISTATINE
PA8589801A1 (en) AMINOALCOXYINDOLS
AR063095A1 (en) THROMBINE RECEIVER ANTAGONISTS BASED ON THE MODIFIED TRICYCLE UNIT OF HIMBACINE
UY29468A1 (en) NEW DERIVATIVES OF ISOINDOLS, COMPOSITIONS THAT CONTAIN THEM, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE, ESPECIALLY AS INHIBITORS OF THE ACTIVITIES OF THE CHAPERONA HSP90 PROTEIN.
UY31854A (en) SUBSTITUTED DERIVATIVES OF 3-OXO-ISOINDOLIN-1- N-SUBSTITUTED CARBOXAMIDS AND APPLICATIONS
MX2007003105A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i.